|
|
Article: Ribozyme Comes Out Strong On First Day As Sirna Therapeutics.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Ribozyme Pharmaceuticals Inc.'s stock shot up 56 percent Thursday after shareholders voted in favor of the company's plans for financing, a name change and a reverse stock split.
As part of the actions, Ribozyme changed its name to Sirna Therapeutics Inc. and has $50 million to $52 million, or enough cash to run the business for four years. "That's pretty good in biotech," said Howard Robin, Sirna's president and CEO, who told BioWorld Today that morale at the company is "very high." Sirna has 28.17 million shares outstanding on a post-split basis.
Before Thursday, Sirna was looking at possible delisting on Nasdaq because the ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|